Overview

A Study to Evaluate Efficacy and Safety of ASP015K in Patients With Rheumatoid Arthritis (RA) Who Had an Inadequate Response to Methotrexate (MTX) Treatment

Status:
Completed

Trial end date:
2017-11-28

Target enrollment:

Participant gender:

Summary

The objective of this study was to verify the efficacy of ASP015K versus placebo administrated in combination with methotrexate (MTX) over placebo in terms of efficacy in participants with rheumatoid arthritis (RA) who had an inadequate response to MTX

Phase:

Phase 3

Details

Lead Sponsor:

Astellas Pharma Inc

Treatments:

Methotrexate
Peficitinib